Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches [Yahoo! Finance]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Yahoo! Finance
combination in refractory MSS metastatic colorectal cancer , with overall survival as the primary endpoint and the study powered to assess both liver and non-liver metastasis subgroups as a registrational pathway. Early clinical data across more than 1,200 patients and multiple tumor types show reproducible activity and durability in historically “cold” tumors—Agenus reports flattening OS curves and treatment-free survival signals, and neoadjuvant NEST/UNICORN cohorts had roughly complete or near-complete responses after a short pre-surgery dosing course. Agenus ended its broad compassionate use program but operates France's AAC and paid named-patient programs, which contributed about $3.2 million in Q4 revenue and generated 270 inquiries from 30 countries, as the company builds medical affairs, real-world evidence, and payer discussions while noting capital needs and a perceived disconnect with its market valuation. Interested in Agenus Inc.? Here are five stocks we like better
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Agenus (AGEN) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Agenus (AGEN) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AGEN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "buy".MarketBeat
- Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy [Yahoo! Finance]Yahoo! Finance
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026Business Wire
AGEN
Earnings
- 11/10/25 - Miss
AGEN
Sec Filings
- 4/6/26 - Form 4
- 4/2/26 - Form 4
- 3/26/26 - Form SCHEDULE
- AGEN's page on the SEC website